Nevertheless, the utilization of dual-targeted inhibitors for PI3K/AKT/mTOR and RAS/ERK signaling pathways is a potentially effective therapeutic approach against ovarian cancer [41]. This evidence concerns the gene PIK3CA and ovarian carcinoma.